X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5707) 5707
Magazine Article (42) 42
Book Chapter (30) 30
Book Review (5) 5
Dissertation (5) 5
Publication (4) 4
Book / eBook (3) 3
Conference Proceeding (1) 1
Newsletter (1) 1
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5140) 5140
female (5043) 5043
index medicus (2064) 2064
middle aged (1911) 1911
obstetrics & gynecology (1735) 1735
progestins - adverse effects (1579) 1579
adult (1488) 1488
postmenopausal women (1421) 1421
risk factors (1344) 1344
estrogen replacement therapy - adverse effects (1277) 1277
menopause (1208) 1208
hormone replacement therapy (1199) 1199
estrogen plus progestin (1129) 1129
women (1091) 1091
aged (1060) 1060
risk (1009) 1009
estrogen (1004) 1004
estrogens - adverse effects (966) 966
progestins - administration & dosage (945) 945
progestins - therapeutic use (864) 864
pregnancy (787) 787
postmenopause (743) 743
hormone therapy (729) 729
progestin (690) 690
animals (590) 590
progesterone (577) 577
health aspects (540) 540
medicine, general & internal (539) 539
contraceptives, oral - adverse effects (523) 523
replacement therapy (519) 519
estrogens - administration & dosage (515) 515
breast cancer (503) 503
estrogen replacement therapy (498) 498
breast neoplasms - chemically induced (482) 482
estrogens - therapeutic use (473) 473
progestins (470) 470
endocrinology & metabolism (462) 462
male (452) 452
oncology (442) 442
prevention (436) 436
randomized controlled-trial (427) 427
hormone replacement therapy - adverse effects (424) 424
randomized controlled trials as topic (413) 413
treatment outcome (405) 405
cancer (397) 397
coronary-heart-disease (395) 395
adolescent (388) 388
progestins - pharmacology (386) 386
breast-cancer (380) 380
obstetrics and gynecology (379) 379
plus progestin (375) 375
estrogens (366) 366
risk assessment (365) 365
time factors (364) 364
prospective studies (360) 360
estradiol (358) 358
oral contraceptives (357) 357
breast neoplasms - epidemiology (355) 355
medroxyprogesterone acetate (354) 354
women's health (345) 345
womens health (335) 335
cardiovascular-disease (321) 321
research (321) 321
hormones (310) 310
estrogen replacement therapy - methods (306) 306
venous thromboembolism (299) 299
double-blind (296) 296
care and treatment (290) 290
internal medicine (287) 287
reproductive biology (285) 285
contraception (279) 279
pharmacology & pharmacy (278) 278
contraceptives, oral, hormonal - adverse effects (276) 276
double-blind method (273) 273
progestogen (273) 273
incidence (267) 267
geriatrics & gerontology (266) 266
case-control studies (265) 265
public, environmental & occupational health (264) 264
conjugated equine estrogens (259) 259
endometrial cancer (258) 258
estradiol - administration & dosage (258) 258
drug therapy, combination (255) 255
progestogens (255) 255
contraceptives, oral, combined - adverse effects (249) 249
medicine & public health (246) 246
osteoporosis (246) 246
analysis (245) 245
cardiovascular diseases - prevention & control (244) 244
abridged index medicus (243) 243
oral-contraceptives (243) 243
cohort studies (234) 234
young adult (230) 230
therapy (229) 229
follow-up studies (226) 226
mortality (226) 226
disease (224) 224
dose-response relationship, drug (220) 220
age factors (217) 217
estrogens - pharmacology (216) 216
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5300) 5300
French (174) 174
German (137) 137
Italian (42) 42
Spanish (42) 42
Swedish (20) 20
Danish (19) 19
Dutch (14) 14
Japanese (12) 12
Norwegian (12) 12
Polish (11) 11
Russian (8) 8
Portuguese (7) 7
Czech (6) 6
Chinese (5) 5
Bulgarian (4) 4
Romanian (3) 3
Serbian (3) 3
Hungarian (2) 2
Croatian (1) 1
Finnish (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2001, Volume 24, Issue 6, 14
... and valproic acid show mostly beneficial effects on the lipd profile. Some drugs, for example, isotretinoin, acitretin and anti... 
Antihypertensives, adverse reactions | Celiprolol, adverse reactions | Retinol, adverse reactions | Diuretics, adverse reactions | Nelfinavir, adverse reactions | Phenytoin, adverse reactions | Retinoids, adverse reactions | Immunosuppressants, adverse reactions | Calcium channel antagonists, adverse reactions | Danazol, adverse reactions | Progestogens, adverse reactions | Hormonal replacements, adverse reactions | Raloxifene, adverse reactions | Phenobarbital, adverse reactions | Acitretin, adverse reactions | Tamoxifen, adverse reactions | Saquinavir, adverse reactions | Alpha adrenoceptor antagonists, adverse reactions | Carbamazepine, adverse reactions | Oral contraceptives, adverse reactions | Anticonvulsants, adverse reactions | Ritonavir, adverse reactions | Indinavir, adverse reactions | ACE inhibitors, adverse reactions | Estrogens, adverse reactions | Growth hormones, adverse reactions | Protease inhibitors, adverse reactions | Antipsychotics, adverse reactions | Clozapine, adverse reactions | Isotretinoin, adverse reactions | Lipid metabolism disorders, drug-induced | Valproic acid, adverse reactions | Beta adrenoceptor antagonists, adverse reactions | Medicine & Public Health | Drug Safety and Pharmacovigilance | Pharmacology/Toxicology | HUMAN-IMMUNODEFICIENCY-VIRUS | POSTMENOPAUSAL ESTROGEN | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | DEPOT-MEDROXYPROGESTERONE ACETATE | PLASMA-LIPIDS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CORONARY-ARTERY-DISEASE | 13-CIS RETINOIC ACID | ORAL-CONTRACEPTIVES | Selective Estrogen Receptor Modulators - therapeutic use | Humans | Hormones - therapeutic use | Adult | Female | Immunosuppressive Agents - adverse effects | Male | Hormones - adverse effects | Cardiovascular Agents - adverse effects | Hyperlipidemias - chemically induced | Hyperlipidemias - prevention & control
Book Review
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0182045
Combined estrogen-progestin preparations (CEPs) are associated with thromboembolic (TE) side effects... 
HORMONAL CONTRACEPTION | SYSTEM DATABASE | SIGNAL-DETECTION | VENOUS THROMBOEMBOLISM | MYOCARDIAL-INFARCTION | THROMBOSIS | ODDS RATIO | MULTIDISCIPLINARY SCIENCES | ORAL-CONTRACEPTIVE USE | SWEDISH WOMEN | RISK | Norgestrel - administration & dosage | Thromboembolism - chemically induced | Desogestrel - adverse effects | Humans | Middle Aged | Progestins - adverse effects | Male | Norgestrel - adverse effects | Estrogens - adverse effects | Norethindrone - administration & dosage | Young Adult | Ethinyl Estradiol - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Norethindrone - adverse effects | Adult | Female | Ethinyl Estradiol - administration & dosage | Contraceptives, Oral, Combined - administration & dosage | Odds Ratio | Child | Databases, Factual | Androstenes - adverse effects | Adverse Drug Reaction Reporting Systems | Japan | Androstenes - administration & dosage | Contraceptives, Oral, Combined - adverse effects | Desogestrel - administration & dosage | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Progestins - administration & dosage | Adolescent | Estrogens - administration & dosage | Progestational hormones | Thromboembolism | Health aspects | Risk factors | Estrogen | Drugs | Ethinylestradiol | Medical equipment | Medical devices | Anemia | Estrogens | Cases (containers) | Risk analysis | Data mining | Patients | Estradiol | Data bases | Incidence | Birth control | Sex hormones | Side effects | Databases | Progestin | Health risk assessment | Pharmaceuticals
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2008, Volume 148, Issue 3, pp. 197 - 213
Journal Article
Blood, ISSN 1528-0020, 2016, Volume 127, Issue 11, pp. 1417 - 1425
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 1, p. CD004143
.... This is an updated version of a Cochrane review first published in 2005. Objectives To assess effects of long‐term HT... 
Estrogen Replacement Therapy | Cardiovascular Diseases | Estrogens | Menopause | PREVENTION AND TREATMENT OF LONG TERM PROBLEMS | CLIMACTERIC/MENOPAUSE | Cause of Death | Neoplasms | Randomized Controlled Trials as Topic | Gynaecology | Venous Thromboembolism | Hot Flashes | Postmenopause | Perimenopause | Progesterone | Medicine General & Introductory Medical Sciences | CONJUGATED EQUINE ESTROGENS | BONE-MINERAL DENSITY | Hot Flashes [drug therapy] | Humans | Middle Aged | Neoplasms [chemically induced; mortality] | Venous Thromboembolism [chemically induced] | BASE-LINE CHARACTERISTICS | COLORECTAL-CANCER INCIDENCE | MEDICINE, GENERAL & INTERNAL | Estrogen Replacement Therapy [adverse effects; methods] | Cardiovascular Diseases [chemically induced; mortality] | Adult | Female | QUALITY-OF-LIFE | ESTROGEN PLUS PROGESTIN | CARDIOVASCULAR RISK-FACTORS | MILD COGNITIVE IMPAIRMENT | Estrogens [adverse effects; therapeutic use] | HEALTH INITIATIVE MEMORY | Aged | Progesterone [adverse effects; therapeutic use] | CORONARY-HEART-DISEASE | Hot Flashes - drug therapy | Neoplasms - mortality | Estrogens - adverse effects | Progesterone - adverse effects | Estrogen Replacement Therapy - adverse effects | Estrogens - therapeutic use | Progesterone - therapeutic use | Estrogen Replacement Therapy - methods | Neoplasms - chemically induced | Venous Thromboembolism - chemically induced | Aged, 80 and over | Cardiovascular Diseases - mortality | Cardiovascular Diseases - chemically induced
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 2, pp. 128 - 137
...) medical treatment in reducing the effect of this problem on quality of life. Heavy menstrual bleeding, or menorrhagia, is a common problem that can have a significant effect on women's lives and can burden both patients and health care systems... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | COST-EFFECTIVENESS | MIRENA | THERMAL BALLOON ABLATION | HYSTERECTOMY | MENSTRUAL PROBLEMS | PATIENT | QUALITY-OF-LIFE | ENDOMETRIAL ABLATION | Contraceptive Agents, Female - adverse effects | Antifibrinolytic Agents - therapeutic use | Follow-Up Studies | Contraceptive Agents, Female - therapeutic use | Progestins - therapeutic use | Humans | Middle Aged | Contraceptive Agents, Female - administration & dosage | Progestins - adverse effects | Antifibrinolytic Agents - adverse effects | Estrogens - adverse effects | Estrogens - therapeutic use | Intrauterine Devices, Medicated | Menorrhagia - surgery | Adult | Female | Severity of Illness Index | Mefenamic Acid - therapeutic use | Sexual Behavior | Mefenamic Acid - adverse effects | Menorrhagia - drug therapy | Tranexamic Acid - therapeutic use | Tranexamic Acid - adverse effects | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Levonorgestrel - therapeutic use | Quality of Life | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Menorrhagia | Levonorgestrel | Women | Birth control | Menstruation | Primary care | Age | Index Medicus | Abridged Index Medicus
Journal Article
2004, Volume 27, Issue 2, 16
.... Adverse... 
Etamsylate, therapeutic use | Tranexamic acid, therapeutic use | Gestrinone, therapeutic use | Nonsteroidal anti inflammatories, adverse reaction | Contraceptives, adverse reactions | Levonorgestrel, adverse reactions | Progestogens, therapeutic use | Danazol, adverse reactions | Progestogens, adverse reactions | Gestrinone, adverse reactions | Contraceptives, therapeutic use | Intrauterine contraceptive device | Mefenamic acid, adverse reactions | Levonorgestrel, therapeutic use | Antifibrinolytics, adverse reactions | Gonadotropin releasing hormone agonists, adverse r | Nonsteroidal anti inflammatories, therapeutic use | Menorrhagia, treatment | Antifibrinolytics, therapeutic use | Etamsylate, adverse reactions | Benefit risk assessment | Danazol, therapeutic use | Mefenamic acid, therapeutic use | Gonadotropin releasing hormone agonists, therapeut | Tranexamic acid, adverse reactions | Medicine & Public Health | Drug Safety and Pharmacovigilance | Pharmacology/Toxicology | MENSTRUAL BLOOD-LOSS | MEFENAMIC-ACID | DEPOT MEDROXYPROGESTERONE ACETATE | CONTRACEPTIVE USE | LEVONORGESTREL INTRAUTERINE SYSTEM | MEDICAL-MANAGEMENT | RANDOMIZED CONTROLLED-TRIAL | TRANEXAMIC ACID | TRANSCERVICAL RESECTION | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PHARMACOLOGY & PHARMACY | TOXICOLOGY | QUALITY-OF-LIFE | Antifibrinolytic Agents - therapeutic use | Contraceptives, Oral, Hormonal - adverse effects | Contraceptives, Oral, Hormonal - therapeutic use | Gestrinone - adverse effects | Risk Assessment | Menorrhagia - drug therapy | Progestins - therapeutic use | Humans | Gonadotropin-Releasing Hormone - adverse effects | Progestins - adverse effects | Treatment Outcome | Antifibrinolytic Agents - adverse effects | Danazol - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Estrogen Antagonists - therapeutic use | Ethamsylate - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Estrogen Antagonists - adverse effects | Ethamsylate - adverse effects | Female | Gestrinone - therapeutic use | Gonadotropin-Releasing Hormone - therapeutic use | Danazol - therapeutic use
Book Review